News & Media

InnoPharma Announces FDA Approval of Decitabine for Injection, a Generic Version of DACOGEN®

DOWNLOAD PDF -  Piscataway, N.J., August 29, 2014 – InnoPharma, Inc. today announced the approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for decitabine for injection, a generic version of Eisai Inc.’s DACOGEN®. InnoPharma developed the generic formulation of decitabine for injection and entered into an agreement with Sandoz, Inc., pursuant to which Sandoz will sell, market and distribute decitabine for injection in the United States. According to IMS data, aggregate U.S. sales of DACOGEN were approximately $251 million for the twelve...

Read More

InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada

DOWNLOAD PDF  –  Piscataway, N.J., July 30, 2014 – InnoPharma, Inc. today announced the first generic launch of Olanzapine for Injection, 10mg/vial (the generic equivalent of Zyprexa® injection), in Canada. Olanzapine is indicated for the rapid control of agitation and disturbed behaviors in patients with schizophrenia or bipolar I mania. As the developer of this generic injectable drug, InnoPharma has entered into an agreement with Sandoz Canada Inc., pursuant to which Sandoz Canada will make, use, sell, market and distribute Olanzapine Injection in Canada. Commenting on today’s news,...

Read More

Pfizer To Acquire InnoPharma,Inc.

DOWNLOAD PDF  – NEW YORK, N.Y., and PISCATAWAY, NJ, July 16 – Pfizer Inc. (NYSE: PFE) and InnoPharma, Inc., a privately held pharmaceutical development company, today announced that they have entered into an agreement under which Pfizer will acquire InnoPharma. Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments. InnoPharma’s current portfolio includes 10 generic products approved by the United States (U.S.) Food and Drug Administration (FDA). The company also has a...

Read More

InnoPharma to Present at the 32nd Annual J.P. Morgan Healthcare Conference

DOWNLOAD PDF – Piscataway, N.J., January 6, 2014 – InnoPharma, Inc., a privately held company focused on developing first to file and first to market opportunities in the complex generic and specialty pharmaceutical product space, is pleased to announce that it is scheduled to present at the 32nd Annual J.P. Morgan Healthcare Conference at 8:00 am PT on January 15, 2014. The conference will be held at the Westin St. Francis Hotel in San Francisco. Navneet Puri, Ph.D., President and Chief Executive Officer of InnoPharma, will provide a company overview during the presentation. A copy of...

Read More

InnoPharma Inc. Completes $20 Million Term Loan Facility

DOWNLOAD PDF – PISCATAWAY, N.J., November 13, 2013 — InnoPharma, Inc today announced that it has closed on a $20 million term loan facility, provided by Athyrium Capital Management through its Athyrium Opportunities Fund. Proceeds will support the Company’s ongoing development of complex generic and innovative specialty pharmaceutical products in injectable and ophthalmic dosage forms. Armentum Partners acted as financial advisors to InnoPharma for this transaction. Navneet Puri, Ph.D., president & CEO of InnoPharma, commented, “This new financing will enhance InnoPharma’s ability...

Read More

InnoPharma Inc. Appoints Vish Shetty as Vice President, Business Development & Alliance Management

DOWNLOAD PDF – PISCATAWAY, N.J., Nov. 11, 2013 — InnoPharma, Inc. today announced the appointment of Vish Shetty to the role of vice president, business development & alliance management. Mr. Shetty has over 10 years of extensive experience in market research, portfolio management, marketing, product launches, business development and strategic planning with pharmaceutical companies. Commenting on the appointment, Navneet Puri, Ph.D., president & CEO of InnoPharma, stated, “The depth and breadth of Vish’s generic and specialty pharmaceutical experience and expertise with...

Read More